Regis Healthcare Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Regis Healthcare (ASX:REG) Full Year 2024 Results

Key Financial Results

• Revenue: AU$1.01b (up 30% from FY 2023).
• Net loss: AU$21.4m (loss narrowed by 25% from FY 2023).
• AU$0.071 loss per share (improved from AU$0.095 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Regis Healthcare Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 9.2%. Earnings per share (EPS) missed analyst estimates by 13%.

In the last 12 months, the only revenue segment was Provision of Residential Aged Care Services contributing AU$1.01b. Notably, cost of sales worth AU$838.8m amounted to 83% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to AU$88.1m (41% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of AU$19.5m. Explore how REG's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Healthcare industry in Australia.

Performance of the Australian Healthcare industry.

The company's shares are up 13% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Regis Healthcare (1 is potentially serious!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.